# EDGAR Filing Document

**Accession Number:** 0001800282
**File Stem:** 0001839882-23-002118
**Filing Date:** 2023-1
**Character Count:** 22624
**Document Hash:** 849319e84887eacf13fbbaf0d7fb8b2b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001839882-23-002118.hdr.sgml**: 20230130

**ACCESSION NUMBER**: 0001839882-23-002118

**CONFORMED SUBMISSION TYPE**: ABS-15G

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230130

**ITEM INFORMATION**: Findings and Conclusions of the Third Party Due Diligence Provider Obtained by the Issuer

**FILED AS OF DATE**: 20230130

**DATE AS OF CHANGE**: 20230130

**ABS RULE**: RULE-15GA2

**REGISTERED ENTITY**: N

**ABS ASSET CLASS**: Other

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Libra Solutions Securitization Funding, LLC
- **CENTRAL INDEX KEY:** 0001800282
- **IRS NUMBER:** 844298362
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** ABS-15G
- **SEC ACT:** Dodd Frank Act
- **SEC FILE NUMBER:** 025-04932
- **FILM NUMBER:** 23569142

**BUSINESS ADDRESS:**
- **STREET 1:** 9525 BRYN MAWR AVENUE, SUITE 900
- **CITY:** ROSEMONT
- **STATE:** IL
- **ZIP:** 60018
- **BUSINESS PHONE:** 8777338140

**MAIL ADDRESS:**
- **STREET 1:** 9525 BRYN MAWR AVENUE, SUITE 900
- **CITY:** ROSEMONT
- **STATE:** IL
- **ZIP:** 60018

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Oasis Securitization Funding, LLC
- **DATE OF NAME CHANGE:** 20200116
**DEPOSITOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Libra Solutions Securitization Funding, LLC
- **CENTRAL INDEX KEY:** 0001800282
- **IRS NUMBER:** 844298362
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** ABS-15G
- **SEC ACT:** Dodd Frank Act

**BUSINESS ADDRESS:**
- **STREET 1:** 9525 BRYN MAWR AVENUE, SUITE 900
- **CITY:** ROSEMONT
- **STATE:** IL
- **ZIP:** 60018
- **BUSINESS PHONE:** 8777338140

**MAIL ADDRESS:**
- **STREET 1:** 9525 BRYN MAWR AVENUE, SUITE 900
- **CITY:** ROSEMONT
- **STATE:** IL
- **ZIP:** 60018

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Oasis Securitization Funding, LLC
- **DATE OF NAME CHANGE:** 20200116

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549<br>** 

<br> **FORM ABS-15G<br>ASSET-BACKED SECURITIZER<br> REPORT PURSUANT TO SECTION 15G OF<br> THE SECURITIES EXCHANGE ACT OF 1934**

**<u>LIBRA SOLUTIONS SECURITIZATION FUNDING, LLC</u>**

Check the appropriate box to indicate the filing obligation to which this form is intended to satisfy:

☐ Rule 15Ga-1 under the Exchange Act (17 CFR 240.15Ga-1) for the reporting period______________ to _________________

Date of Report (Date of filing) __________________

Commission File Number of securitizer: __________________

Central Index Key Number of securitizer:__________________

Name and telephone number, including area code, of the person<br> to contact in connection with this filing.

Indicate by check mark whether the securitizer has no activity to report for the initial period pursuant to Rule 15Ga-1(c)(l) ☐

Indicate by check mark whether the securitizer has no activity to report for the quarterly period pursuant to Rule 15Ga-1(c)(2)(i) ☐

Indicate by check mark whether the securitizer has no activity to report for the annual period pursuant to Rule 15Ga-1(c)(2)(ii) ☐

☒ Rule 15Ga-2 under the Exchange Act (17 CFR 240.15Ga-2)

Central Index Key Number of depositor: <u>0001800282</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>LIBRA SOLUTIONS 2023-1 LLC</u> <br> (Exact name of issuing entity as specified in its charter)

Central Index Key Number of issuing entity (if applicable): <u>Not applicable</u>

Central Index Key Number of underwriter (if applicable): <u>Not applicable</u> 

Shiven Shah, (646) 732-5900

Name and telephone number, including area code, of the person<br> to contact in connection with this filing.

**FINDINGS AND CONCLUSIONS OF THIRD-PARTY DUE DILIGENCE REPORTS**

**Item 2.01 Findings and Conclusions of a Third Party Due Diligence Report Obtained by the Issuing Entity**

The disclosures required by Rule 15Ga-2 (17 CFR 240.15Ga-2) are attached as Exhibit 99.1 to this Form ABS-15G. Please see the Exhibit Index for the related information.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the reporting entity has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LIBRA SOLUTIONS SECURITIZATION FUNDING, LLC

Date: January 30, 2023

By: <u>/s/Shiven Shah</u> 

Name: Shiven Shah

Title: Chief Financial Officer

**EXHIBIT INDEX**

<u>Exhibit Number</u>

[99.1](ex99-1.htm) Independent Accountant's Report on Applying Agreed-Upon Procedures, dated January 30, 2023

## Exhibit 99.1

[LIBRA SOLUTIONS 2023-1 LLC ABS-15G](libra-abs15g_013023.htm)

**Exhibit 99.1**

![](libra-002.jpg)

**grant thornton llp**<br> 171 N. Clark Street, Suite 200<br> Chicago, IL 60601<br>**D** +1 312 856 0200<br> **F** +1 312 602 8099 <br>

**REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS**

Board of Directors and Management of Libra Solutions Intermediate Holdco LLC, Libra 2023-1 LLC and Amherst Pierpont Securities LLC:

Grant Thornton ("Grant Thornton", or "we") has performed the procedures enumerated below, on certain information with respect to attributes of Libra Solutions Intermediate Holdco LLC's (the "Company") plaintiff and medical lien receivables as of January 17, 2023 (the "Subject Matter") related to Libra 2023-1 LLC's (the "Issuer") issuance of certain classes of Notes (the "Securitization Transaction"). The Company's management is responsible for the Data File (as defined herein) accurately representing the information included in the underlying asset documents and the disclosed assumptions and methodologies.

The Company has agreed to and acknowledged that the procedures performed are appropriate to meet the intended purpose of assisting specified parties in evaluating the Subject Matter. This report may not be suitable for any other purpose. Additionally, the Issuer and Amherst Pierpont Securities LLC ("Amherst" and together with the Company and Issuer, the "Specified Parties") have agreed to and acknowledged that the procedures performed are appropriate for their purposes. The procedures performed may not address all the items of interest to a user of this report and may not meet the needs of all users of this report and, as such, users are responsible for determining whether the procedures performed are appropriate for their purposes.

Consequently, we make no representation regarding the appropriateness of the procedures enumerated below either for the purpose for which this report has been requested or for any other purpose.

The procedures performed on the plaintiff and medical lien receivables and associated findings are as detailed in Sections A and B herein and Appendix B. At the Company's instruction, for the purposes of our procedures, (i) differences of less or equal to $50, as applicable, were deemed to be in agreement, (ii) different forms of the same first name (for example Deb vs. Debbie vs. Deborah) were deemed to be in agreement and (iii) for the following date related Characteristics, differences of less than or equal to:

- 5 business days for the Funding Date Characteristic

- 30 days for the Payment Date Characteristics

- 90 days for the Invoice Date Characteristic

were deemed to be in agreement. Unless otherwise indicated, the following are defined for the purposes of our procedures:

· the phrase "compared" means we checked the information
for agreement between sources, with any findings being reported unless a deviation tolerance is otherwise noted. If applicable, such compared amounts and percentages
are deemed to be in agreement if differences were attributable to rounding.

GT.COM Grant Thornton LLP is the U.S. member firm of Grant Thornton International Ltd (GTIL). GTIL and each of its member firms are separate legal entities and are not a worldwide partnership.

![](libra-002.jpg)

· the phrase "recomputed" means, if applicable,
we recalculated the number through mathematical calculation using the applicable information in the Data File as the inputs, with any
findings being reported unless a deviation tolerance is otherwise noted. If applicable, such recomputed amounts and percentages are deemed
to be in agreement if differences were attributable to rounding.

· the phrase "Source Documents" means a record containing
details of a particular transaction or characteristic. Source Documents include the Contract, Lien, Attorney Letter, Letter of Protection,
Funding Application, Payable Check Voucher, ACH Screenshot or Invoice ("Payment Support"), Checks, Bank Statements, LIBRA
23-1 MedLien Vendor Name table and screenshots from the Company's internal accounting systems ("System Application").

Due diligence agreed-upon procedures

**A.** **Data Tape Agreed Upon Procedures** 

On January 18, 2023, the Company provided us with computer readable data files (the "Initial Data Files") containing certain characteristics of the plaintiff and medical lien receivables (the "Plaintiff and Medical Lien Receivables") included in the Securitization Transaction. The Company provided us with periodic updates received up to and including January 27, 2023 (together with the Initial Data Files, the "Databases"). We performed the procedures indicated below on the Plaintiff and Medical Lien Receivables.

As instructed by the Company, Grant Thornton selected, on a random basis, sixty-four (64) plaintiff receivables ("Plaintiff" or "Presettlement") from the Libra 2023-1 - Pre-set (1.17.2023)v2.xlsb Data File, and thirty-six (36) medical lien receivables ("Medical" or "Non-Presettlement") from the Libra 2023-1 - Med LIen (1.17.2023)v2.xlsb for a total of 100 receivables, (collectively, the "Sample Assets"). For each of the Sample Assets listed on Appendix A, we performed comparisons for certain characteristics (as identified in Exhibit 1) to certain available source documents (the "Source Documents").

**Exhibit 1**

**Characteristics:**

---

| | | | |
|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Characteristic** | &nbsp;&nbsp;**Source Document** | &nbsp;&nbsp;**Type** |
| &nbsp;&nbsp;1 | &nbsp;&nbsp;Case Number | &nbsp;&nbsp;Contract, Screen Images from the Company's accounting systems ("System Application"), Payment Support | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;2 | &nbsp;&nbsp;Funding Date | &nbsp;&nbsp;Contract, System Application | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;3 | &nbsp;&nbsp;Customer Name | &nbsp;&nbsp;Contract, System Application, Credit Application | &nbsp;&nbsp;Plaintiff |

---

![](libra-002.jpg)

---

| | | | |
|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Characteristic** | &nbsp;&nbsp;**Source Document** | &nbsp;&nbsp;**Type** |
| &nbsp;&nbsp;4 | &nbsp;&nbsp;Funding Amount | &nbsp;&nbsp;Contract, System Application, Payment Support | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;5 | &nbsp;&nbsp;Principal Balance Outstanding | &nbsp;&nbsp;Contract, System Application | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;6 | &nbsp;&nbsp;Last Payment Date | &nbsp;&nbsp;Contract, System Application | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;7 | &nbsp;&nbsp;Receivable Type | &nbsp;&nbsp;Contract, System Application | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;8 | &nbsp;&nbsp;Vendor | &nbsp;&nbsp;Contract, System Application, Payment Support, LIBRA 23-1 MedLien Vendor Name table | &nbsp;&nbsp;Medical |
| &nbsp;&nbsp;9 | &nbsp;&nbsp;Patient ID | &nbsp;&nbsp;Contract, System Application, Payment Support, | &nbsp;&nbsp;Medical |
| &nbsp;&nbsp;10 | &nbsp;&nbsp;UPV (Site Cost) | &nbsp;&nbsp;Contract, System Application, Payment Support | &nbsp;&nbsp;Medical |
| &nbsp;&nbsp;11 | &nbsp;&nbsp;Invoice Date | &nbsp;&nbsp;Contract, System Application, Payment Support | &nbsp;&nbsp;Medical |
| &nbsp;&nbsp;12 | &nbsp;&nbsp;Payment Date | &nbsp;&nbsp;Contract, System Application | &nbsp;&nbsp;Medical |
| &nbsp;&nbsp;13 | &nbsp;&nbsp;Principal Balance Outstanding | &nbsp;&nbsp;Contract, System Application | &nbsp;&nbsp;Medical |

---

For Characteristic 1, for comparison purposes, we were instructed by the Company to remove the "- #" or "- ##", where # represents any digit, from the end of the Case Number in the Initial Data Files.

For Characteristic 2, for those Sample Assets where there is greater than a 5 day difference in the comparison between the Database and the Contract Date, we were instructed by the Company to perform an additional comparison to the signature date on the contract. For those Sample Assets that still have a greater than 5 day difference, we were instructed by the Company to compare the funding date on the Payoff Breakdown Screenshot extract from the System Application to the Database.

For Characteristic 3, we were instructed by the Company to compare only the first and last name and to disregard any middle initial, middle name or suffix.

For Characteristic 8, we were instructed by the Company that the name of the Vendor can be supported by either the Payee or Vendor name on the Payable Check Voucher or ACH Screenshot. For those Sample Assets where the Patient ID in the Database does not match the Vendor in the Source Documents, we were instructed by the Company to use the LIBRA 23-1 MedLien Vendor Name table provided by the Company to identify the Vendor.

We noted 1 discrepancy in connection with the characteristics listed in Exhibit 1 between the Database and the Source Documents as listed in Appendix B.

![](libra-002.jpg)

**B.** **Documentation Agreed Upon Procedures** 

For each of the Plaintiff Sample Assets, Grant Thornton observed the existence of the following documentation, or compared and agreed information contained within the following documentation (as described below):

- Inspected the existence of a Funding Application;

- Inspected the existence of a Signed Contract;

- Both the customer and Attorney signed the contract, or if the Attorney has not signed the contract, the presence of an Attorney Letter

Compared and agreed the Name on the Funding Application to the Signed Contract. For those Sample Assets where the Name on the Funding Application does not match the name on the Signed Contract, we were instructed by the Company to use the Name Matrix provided by the Company to compare against the Signed Contract.

For each of the Medical Lien Sample Assets, Grant Thornton observed the existence of the following documentation, or compared and agreed information contained within the following documentation (as described below):

- Inspected the signed Contract for signatures from the Company and vendor

- Compared and agreed the Patient ID to the related invoice / Check Payable Voucher/ACH Screenshot

- Compared and agreed the name of the medical facility (vendor) to the signed Contract

- Inspected the presence of a signed lien by either the patient or the patient's attorney

- For those Medical Sample Assets without a lien, inspected that a Letter of Protection ("LOP") was obtained

We noted 2 discrepancies in documentation as listed in Appendix B.

We were engaged by the Company to perform this agreed-upon procedures engagement and conducted our engagement in accordance with attestation standards established by the American Institute of Certified Public Accountants. We were not engaged to and did not conduct an examination or review, the objective of which would be the expression of an opinion or conclusion, respectively, on the Subject Matter. Accordingly, we do not express such an opinion or conclusion. Had we performed additional procedures, other matters might have come to our attention that would have been reported to you.

![](libra-002.jpg)

Our agreed-upon procedures engagement was not conducted for the purpose of the following:

· Addressing the conformity of the origination of the assets
to stated underwriting or credit extension guidelines, standards, criteria, or other requirements

· Addressing the value of collateral securing any such assets
being securitized

· Addressing the compliance of the originator of the assets
with federal, state, and local laws and regulations

· Satisfying any criteria for due diligence published by a nationally
recognized statistical rating organization

· Addressing any other factor or characteristic of the assets
that would be material to the likelihood that the issuer of the asset-backed security will pay interest and principal in accordance with
applicable terms and conditions

· Forming any conclusions

· Any other terms or requirements of the transaction that do
not appear in this report.

We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements related to our agreed-upon procedures engagement.

This report is intended solely for the information and use of the Specified Parties. It is not intended to be, and should not be, used by anyone other than these specified parties, including investors and rating agencies, who are not identified as specified parties but who may have access to this report as required by law or regulation.

Chicago, Illinois

January 30, 2023

![](libra-002.jpg)

**Appendix A**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Selection**<br> **#** | &nbsp;&nbsp;**Plaintiff Sample Assets**<br> **Identifier** | &nbsp;&nbsp;**Selection**<br> **#** | &nbsp;&nbsp;**Plaintiff Sample Assets**<br> **Identifier** | &nbsp;&nbsp;**Selection**<br> **#** | &nbsp;&nbsp;**Plaintiff Sample Assets**<br> **Identifier** |
| &nbsp;&nbsp;1 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;23 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;45 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;2 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;24 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;46 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;3 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;25 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;47 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;4 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;26 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;48 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;5 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;27 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;49 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;6 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;28 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;50 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;7 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;29 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;51 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;8 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;30 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;52 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;9 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;31 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;53 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;10 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;32 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;54 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;11 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;33 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;55 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;12 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;34 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;56 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;13 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;35 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;57 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;14 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;36 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;58 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;15 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;37 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;59 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;16 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;38 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;60 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;17 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;39 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;61 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;18 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;40 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;62 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;19 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;41 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;63 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;20 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;42 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;64 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;21 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;43 | &nbsp;&nbsp;[Redacted] |  |  |
| &nbsp;&nbsp;22 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;44 | &nbsp;&nbsp;[Redacted] |  |  |
| &nbsp;&nbsp;**Selection**<br> **#** | &nbsp;&nbsp;**Medical Lien Sample**<br> **Assets Identifier** | &nbsp;&nbsp;**Selection**<br> **#** | &nbsp;&nbsp;**Medical Lien Sample**<br> **Assets Identifier** | &nbsp;&nbsp;**Selection Medical**<br> **#** | &nbsp;&nbsp;**Lien Sample Assets**<br> **Identifier** |
| &nbsp;&nbsp;1 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;14 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;27 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;2 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;15 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;28 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;3 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;16 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;29 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;4 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;17 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;30 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;5 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;18 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;31 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;6 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;19 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;32 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;7 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;20 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;33 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;8 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;21 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;34 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;9 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;22 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;35 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;10 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;23 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;36 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;11 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;24 | &nbsp;&nbsp;[Redacted] |  |  |
| &nbsp;&nbsp;12 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;25 | &nbsp;&nbsp;[Redacted] |  |  |
| &nbsp;&nbsp;13 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;26 | &nbsp;&nbsp;[Redacted] |  |  |

---

![](libra-002.jpg)

**Appendix B**

---

| | | | |
|:---|:---|:---|:---|
| **Identifier** | **Characteristic** | **Value per Database** | **Value per Source Documents** |
| [Redacted] | Principal Balance Outstanding | 1653.00 | 1425.00 |
| [Redacted] | Presence of a Signed Lien or LOP | Yes | No |
| [Redacted] | Presence of a Signed Lien or LOP | Yes | No |

---